DOCSLIB.ORG

Research Report 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Research Report 2018 Research Report 2018 A Message from Executive Vice President Gilbert White, II, MD, Chief Scientific Officer 2018 was another strong year for research. Grant and Yan Qing Ma were promoted to Investigator. revenues for the year were $16.1 M, another record Lisa Baumann-Kreuziger, Lynn Malec, and Matt for us and exceeding our 2018 budget by $1 M. Karafin were promoted to Associate Investigator. New NIH R-type grants or competitive renewals Jorge DiPaola of the University of Colorado, David were obtained by Bob Montgomery and by Sandy Lillicrap and Paula James from Queens University in Haberichter. Peter Newman successfully competed Kingston, Canada, James O’Donnell from the Royal for a $6.9 M 7-year R35 Career award from NHLBI. College of Surgeons of Ireland, and Amy Shapiro Karin Hoffmeister received a new $4.8 M K12 award from the Indiana Hemophilia and Thrombosis Center in Glycobiology, one of four in the US together with in Indianapolis were appointed as adjunct Senior Johns Hopkins, Harvard, and UCSD. Gil White is the Investigators at the BRI. PI on a new $1.5 M OT2 consortium grant from NIH that is part of the NIH Precision Medicine Initiative. A Individual accomplishments during the year were new F-type award went to Puja Agrawal in Sid Rao’s numerous. We celebrated Hardy Weiler’s and Pam lab. Altogether, there were 11 new NIH grants in 2018 Christopherson’s 20th year with the organization. that totaled $17.5 M. Nan Zhu received the second Alan Mast chaired the 2018 Hemostasis Gordon R. Douglas Ziegler Innovation Award for her work Conference. Irene Hernandez in Hardy Weiler’s lab related to the pathogenesis of acute myelogenous received Excellence in Action recognition from Versiti. leukemia. Matt Karafin, Josh Field, Peter Newman, Dick Aster received the BizTimes Media Health Care Karin Hoffmeister, and Subra Malarkannan received Heroes Lifetime Achievement Award, recognizing funding for Versiti Moonshot projects. his advancements in transfusion medicine. Karin Hoffmeister chaired the Megakaryocyte and Platelet John Pulikkan joined the faculty as Associate Scientific Committee and the Committee Program Investigator in the stem cell group. John came from the at the annual meeting of the American Society of University of Massachusetts Medical School from the Hematology (ASH). Hervé Falet also serves on the lab of Lucio Castilla, a former scholar of the Leukemia Megakaryocyte and Platelet Scientific Committee. and Lymphoma Society. His research focuses on Peter Newman serves on the Investment and Audit chromatin dynamics and understanding the regulatory Committee of ASH. Alan Mast, Karin Hoffmeister, pathways that are deregulated in hematopoietic stem Magda Chrzanowska, Debra Newman, Roy and progenitor cells in acute myeloid leukemia in order Silverstein and Bob Montgomery continue to serve to better understand the development of leukemia. on NIH review panels. Peter Newman continues His overall goal is to develop novel therapeutic to serve as Associate Editor of Arteriosclerosis, strategies for the treatment of leukemia. Jieqing Zhu Thrombosis, and Vascular Biology (ATVB). Hardy Research Report 2018 1 Continued: A Message from Executive Vice President Gilbert White, II, MD, Chief Scientific Officer Weiler and Roy Silverstein serve on the ATVB Editorial University, on November 8th. His talk was titled “T Zheng in Demin Wang’s lab was the 2018 Doolittle Board. Alan Mast is a new Associate Editor of the Cell Exhaustion and PD-a Immunotherapy”. All four Fellow and Saravanan Subramaniam in Hardy Weiler’s Journal of Thrombosis and Haemostasis. Magda lectures were outstanding and examples of cutting lab was the Gallagher Fellow. Waseem Anani in Karin Chrzanowska is on the Editorial Board of Plos One. edge science and translation. Hoffmeister’s lab was named the first Jaqueline and Bonnie Dittel is Associate Editor of Autoimmunity Arlen Fredrick Scholar. New Directors Fellows were and on the Editorial Boards of the Journal of The 1st Annual Great Lakes Translational Glycomics Heather Ashwood in Karin Hoffmeister’s lab and Neuroimmunology and Brain, Behavior, and Immunity. Symposium was held May 31st at the Blood Amy Siebert-McKenzie in Alan Mast’s lab, bringing Subra Malarkannan is Associate Editor of Frontiers in Research Institute (BRI) and was organized by Karin to 6 the number who have been supported through Immunology. Qizhen Shi is on the Editorial Board of Hoffmeister. Featuring speakers from GlycoMimetics, the contributions of Scott and Genevieve Harkness. Molecular Therapy, Methods and Clinical Development. Inc, Washington University in St. Louis, Virginia Chao Yang in Subra Malarkannan’s lab received the Peter Newman is Co-Editor of the 3rd Edition of Commonwealth University, Roswell Park Cancer inaugural J. Evan Sadler Graduate Scholar Award, as Platelets and Gil White is Co-Editor of the 6th Edition of Center, Brigham and Women’s Hospital, and Medical voted by the BRI graduate students and postdoctoral Thrombosis and Hemostasis. Six students completed College of Wisconsin (MCW), it was attended by more fellows. Moua Yang in Roy Silverstein’s lab received the their PhD degrees in 2018: Michael Reimer from Sid than 60 individuals. The 12th Annual Center for Human Mary Rodes Gibson Memorial Award in Hemostasis Rao’s lab, Aye Myat Myat Thinn from Jieqing Zhu’s Immunology Symposium was held October 25th at and Thrombosis for the highest scoring abstract at lab, David Schauder from Weiguo Cui’s lab, Alex Abel the BRI. The symposium, titled “B Cells and Broadly the American Society of Hematology meeting. Five from Subra Malarkannan’s lab, Erin Wesley from Matt Neutralizing Antibodies,” featured renowned speakers new graduate students selected the BRI as their place Riese’s lab, and Moua Yang from Roy Silverstein’s lab. from Harvard University, Scripps Research Institute, to train: Paytsar Topchyan and Christine Nguyen Vanderbilt University, the Feinstein Institute for Medical in Weiguo Cui’s lab, Yaling Wu in Demin Wang’s lab, The 16th Annual Aster Lecture was delivered on Research, and Sanofi Pharmaceuticals. This year’s Savannah Neu in Bonnie Dittel’s lab, and Yuanhua Cai August 15th by Dr. Olja Finn, Distinguished Professor meeting was hosted by Demin Wang and Renren Wen. in Qizhen Shi’s lab. of Immunology and Surgery at the University of Pittsburgh. Her talk was titled “Vaccines in the The Scientific Advisory Board reviewed part of the Sadly, we lost a long-time and beloved colleague Prevention of Non-Viral Cancers”. The 17th Annual Vascular Biology program in October. Overall, there when Joan Gill passed away on May 9, 2018. Joan Mosesson Lecture was delivered on October 4th was high enthusiasm for this group of investigators. In was internationally renowned in the world of bleeding by Dr. Bjorn Dahlback, Senior Professor in the their summary comments, the Board described the disorders and made a number of lasting contributions Department of Laboratory Medicine at Lund University need for continued succession planning, space for through her work with von Willebrand disease and in Malmo, Sweden. His talk was on “Novel Insights continued expansion, attention to retention, and the hemophilia. One of the first women in the field, Joan into the Regulation of Blood Coagulation by FV success of the mentoring program. They also reported served as an example to countless young women in Isoforms, TFPI alpha and Protein S”. The 2nd Annual some faculty anxiety regarding a perceived emphasis hematology and was the face of bleeding disorders Jacqueline Fredrick Lecture, selected and hosted by on cell therapies and uncertainty regarding changes in care in the State of Wisconsin. the graduate students and postdoctoral fellows at the leadership. BRI, was given on September 20th by Melanie Cobb, At years’ end, there were 38 trainees in the BRI. All of Browning Chair in Medical Science in the Department our T32 Training Grant positions were filled in 2018: of Pharmacology at the UT Southwestern Medical Tyce Kearl in Subra Malarkannan’s lab, Alyssa Moroi Center. The talk was titled “Catching a Few Good in Peter Newman’s lab followed by Lauren Pommert in WNKs”. The 2nd Annual R. Douglas Ziegler Innovation Sid Rao’s lab, Nate Schloemer in Subra Malarkannan’s Lecture was by Dr. Rafi Ahmed, Director of the highly lab followed by Amy Siebert-McKenzie in Alan Mast’s Gilbert C. White, II, MD innovative Harrington Discovery Institute at Emory lab, and Jesse Sundlov in Peter Newman’s lab. Yongwei Chief Scientific Officer 2 Research By The Numbers – 2018 10 $122.4 5 New NIH Million New Diagnostic Grants New Applications Tests Developed $16.1 33 Million 1 Start-Up Company Investigators Research Formed Revenues $614+ 2 13 Thousand Patents Filed Core Labs Average Funding per Investigator Research Report 2018 3 Transfusion Medicine Transfusion Medicine research has a long history at Versiti, reflecting its basic mission to provide a safe and effective supply of blood products for patients who require transfusion. Effective transfusion therapy requires knowledge of the biology and physiology of blood, satisfactory methods for collecting and storing blood cells with maximum preservation of function, and an understanding of the many diseases in which transfusion of blood components can be beneficial. Research conducted by the Transfusion Medicine group addresses each of these areas. Investigators in the Transfusion Medicine Program study basic biology and clinical implications of a range of transfusion-related issues. CEO Emeritus and Senior Investigator, Blood Research Institute Richard H. Aster, MD Professor, Department of Medicine, Medical College of Wisconsin (MCW) MD, University of Michigan 1957 Hematology, Harvard University 1965 Faculty, Harvard 1964-1970 Started at Versiti: 1971 cell destruction and improved understanding of the Funding molecular basis for these conditions. RO1-HL-13629-47 National Heart Lung and Blood Awards, Honors and Service Institute. Renewed June 1, 2017 • Founder: GTI Diagnostics (subsidiary of VBRIF) Publications • Karl Landsteiner Award, American Association of Blood 1.
Load more

Recommended publications
  • Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver
    Confidential Page 1 of 80 Donor-Alloantigen-Reactive Regulatory T Cell Therapy in Liver Transplantation Version 7.0/ August 1, 2018 IND# 15479 Study Sponsor(s): The National Institute of Allergy and Infectious Diseases (NIAID) Grant #: R34AI095135 and U01AI110658-01 Study Drug Manufacturer/Provider: Sanofi US PRINCIPAL INVESTIGATOR CO- PRINCIPAL INVESTIGATOR CO- PRINCIPAL INVESTIGATOR SANDY FENG, MD, PHD JEFFREY BLUESTONE, PHD SANG-MO KANG, MD, FACS Professor of Surgery Executive Vice Chancellor and Provost Associate Professor Director, Abdominal Transplant A.W. Clausen Distinguished Professor University of California, San Surgery Fellowship in Medicine Francisco University of California, San University of California, San Francisco 513 Parnassus Ave. Francisco 513 Parnassus Ave. Box 0780, HSE-520 505 Parnassus Ave. Box 0400, HSW-1128 San Francisco, CA 94143-0780 Box 0780, M-896 San Francisco, CA 94143-0780 Phone: (415) 353-1888 San Francisco, CA 94143-0780 Phone: (415) 476-4451 E-mail: Sang- Phone: (415) 353-8725 Fax: (415) 476-9634 [email protected] Fax: (415) 353-8709 E-mail: [email protected] E-mail: [email protected] CO- PRINCIPAL INVESTIGATOR BIOSTATISTICIAN MEDICAL OFFICER QIZHI TANG, PHD DAVID IKLÉ, PHD NANCY BRIDGES, MD Associate Professor Senior Statistical Scientist Chief, Transplantation Branch Director, UCSF Transplantation Rho, Inc. Division of Allergy, Immunology, Research Lab 6330 Quadrangle Drive and Transplantation University of California, San Chapel Hill, NC 27517 NIAID Francisco Phone: (910) 558-6678
    [Show full text]
  • Java Based Distributed Learning Platform
    Journal of Pharmacy and Pharmacology 8 (2020) 110-123 doi: 10.17265/2328-2150/2020.04.003 D DAVID PUBLISHING Blood Group Cartography (ABO, RHESUS, KELL and DUFFY) and Hemogram of Icteric Newborn in Sendwe Hospital, Lubumbashi/D.R.C Monga Kalenga J. J1, Monga Ngoy Davidson2, Matanda Kapend Serge3, Masendu Kalenga Paulin4, Haumont Dominique5 and Luboya Numbi Oscar1 1. Department of Pediatrics, Faculty of Medicine, University of Lubumbashi, Haut-Katanga 1825, DRC. 2. Laboratory Department Head Sendwe Hospital, Haut Katanga, Lubumbashi 1825, DRC 3. Department of Internal Medicine, Faculty of Medicine, University of Lubumbashi, Haut-Katanga 1825, DRC. 4. CHR The Citadel, Neonatology Department, University of Liège, Liège 4450, Belgium. 5. Free University of Brussels, Brussels 1050, Belgium Abstract: Background: Allo immunization jaundice is a common cause of neonatal jaundice. According to racial group the concerned blood group may not be the same. In our Country people are exposed to high transfusionnal risk because of malaria and sicklanemia and the blood group research in laboratory include only ABO/D. Objective: Our objective was to establish a blood group cartography of this icteric newborn population and their mother; the frequency of rare blood group and the compatibility level between mother and newborn. Our interest was also to study hemogram of this population. Methodology: We studied blood group ABO/D; RH/Kell and Duffy of 56 newborn whom developped an indirect bilirubin and their mothers. We performed bilrubin level and hemogram. Results: The frequency of icteric newborn was 17.17%. The mother blood mapping was O (60.71%), RhD positive (83.9%), C negative (91.07%) E negative (89.29%) c positive (91.07%), epositive (92.86%), kell negative (100%) and duffy null (100%).
    [Show full text]
  • Humoral Alloimmunity in Cardiac Allograft Rejection
    Humoral alloimmunity in cardiac allograft rejection Jawaher Alsughayyir Darwin College Department of Surgery University of Cambridge This dissertation is submitted for the degree of Doctor of Philosophy July 2018 i Declaration This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except where declared in the text. It has not been submitted in whole or part for a degree at any university. The length of this thesis does not exceed the 60,000 word limit i Dissertation title: Humoral alloimmunity in cardiac allograft rejection Student name: Jawaher Alsughayyir Abstract Although the short-term outcomes of solid allograft survival have improved substantially over the last few decades, there has been no significant improvement in long-term survival of solid allografts. This thesis presents the initial characterisation of alloantibody mediated rejection in a murine heart transplant model, with particular focus on the impact of the different phases of the humoral alloimmune response (follicular or germinal centre) on graft rejection. The key findings of this work are: 1) The precursor frequency of allospecific CD4 T cells determines the magnitude of the alloantibody response, with a relatively high frequency of CD4 T cells eliciting strong extrafollicular responses, while a high frequency of B cells promotes slowly-developing germinal centre responses. 2) Strong extrafollicular antibody response can mediate acute heart allograft rejection in the absence of CD8 T cells alloresponses. 3) Germinal centre humoral immunity mediates chronic antibody-mediated rejection. 4) Recipient memory, but not naïve, CD4 T cells that recognise one graft alloantigen can provide ‘unlinked’ help to allospecific B cells that recognise a different graft alloantigen for generating germinal centre alloantibody responses.
    [Show full text]
  • Investigation of Penicillamine-Induced Autoimmunity
    Mechanistic Investigation of Penicillamine-Induced Autoimmunity: Covalent Binding of Penicillamine to Macrophages, Involvement of Th17 cells, and Its Relation to Idiosyncratic Drug-induced Liver Injury By Jinze Li A thesis submitted in conformity with the requirements for the degree of DOCTOR OF PHILOSOPHY Graduate Department of Pharmaceutical Sciences University of Toronto ©Copyright by Jinze Li 2009 Library and Archives Bibliothèque et Canada Archives Canada Published Heritage Direction du Branch Patrimoine de l’édition 395 Wellington Street 395, rue Wellington Ottawa ON K1A 0N4 Ottawa ON K1A 0N4 Canada Canada Your file Votre référence ISBN: 978-0-494-61128-9 Our file Notre référence ISBN: 978-0-494-61128-9 NOTICE: AVIS: The author has granted a non- L’auteur a accordé une licence non exclusive exclusive license allowing Library and permettant à la Bibliothèque et Archives Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par télécommunication ou par l’Internet, prêter, telecommunication or on the Internet, distribuer et vendre des thèses partout dans le loan, distribute and sell theses monde, à des fins commerciales ou autres, sur worldwide, for commercial or non- support microforme, papier, électronique et/ou commercial purposes, in microform, autres formats. paper, electronic and/or any other formats. The author retains copyright L’auteur conserve la propriété du droit d’auteur ownership and moral rights in this et des droits moraux qui protège cette thèse. Ni thesis. Neither the thesis nor la thèse ni des extraits substantiels de celle-ci substantial extracts from it may be ne doivent être imprimés ou autrement printed or otherwise reproduced reproduits sans son autorisation.
    [Show full text]
  • Molecular Identification of T Cells That Respond in a Primary Bulk Culture
    Molecular Identification of T Cells That Respond in a Primary Bulk Culture to a Peptide Derived from a Platelet Glycoprotein Implicated in Neonatal Alloimmune Thrombocytopenia Krystyna Maslanka, Maryam Yassai, and Jack Gorski Immunogenetics Research Section, Blood Research Institute, The Blood Center of Southeastern Wisconsin, Milwaukee, Wisconsin 53201-2178 Abstract Among these, the platelet alloantigen system associated with surface integrin GPIIb/IIIa (␣IIb␤3) plays an important role in Neonatal alloimmune thrombocytopenia induced by the hu- pregnancy and transfusion related alloimmunity (1, 2). man platelet alloantigen 1a (HPA1a) is characterized by A characteristic of these alloimmune responses is the pres- generation of alloantibodies by a mother who is homozy- ence of circulating antibodies specific for the alloantigen. These gous for the HPA1b alloantigen and almost always HLA- are thought to mediate the destruction of the cells expressing DRB3*0101. The disease is viewed as B cell mediated but the alloantigen. One particular alloimmune response is inter- the linkage with HLA is indicative of a role for T cells. The esting in its HLA restriction. The GPIIb/IIIa alloantigens HPA1a and HPA1b allotypes are defined, respectively, by HPA1a and HPA1b are defined by antibodies which are sensi- Leu and Pro at amino acid 33 of the ␤-chain of the platelet tive to the polymorphism at position 33 of the GPIIIa chain integrin GPIIbIIIa (␣IIb␤3). Under the assumption that the (3). Mutagenesis experiments have shown that this polymor- same polymorphism may control both the B cell epitope and phism is sufficient for inducing alloantibody recognition (4). constitute the MHC-bound peptide, we restimulated PBMC The generation of a response to HPA1a (GPIIIaLeu33) requires from a woman with an affected child with a synthetic pep- that the responder be HPA1b (GPIIIaPro33) homozygous.
    [Show full text]
  • Immune Approach to Primary Graft Dysfunction
    Immune approach to Primary Graft Dysfunction Ankit Bharat MD FACS Harold & Margaret Method Professor Director, Lung Transplant & ECMO Disclosures None PRIMARY GRAFT DYSFUNCTION • Incidence >50-70% • Occurs within first 24 hours following transplant • Characterized by respiratory failure • Leading cause of short-term mortality • Predominant risk factor for chronic rejection PGD INDUCES CYTOKINE STORM AND ALLOIMMUNITY Bharat et al, Annals Thor Surg, 2011 Spectrum of PGD Neutrophil-mediated Ischemia- Donor non-classical monocytes allograft injury reperfusion injury Recipient classical monocytes Donor Pneumonia Donor Alveolar Macrophages Donor-specific antibodies Complement activation Antibody-mediated rejection Immune complex deposition Monocyte/macrophage activation (hyperacute/acute) Lung-restricted antibodies Inadequate allograft Endothelial Necroptosis preservation damage NEUTROPHILS MEDIATE PGD Kreisel D et al. J Clin Invest 2011;121:265–276. PERFUSED HUMAN DONOR LUNGS CONTAIN MONOCYTES Bharat et al, AJRCMB, Jan 2016 Zhikun et al, Science Transl Med, 2017 Demonstration of non-classical monocytes in the intravascular space of donor lungs Human Mouse NCM CM Neutrophils n o i s u f r e p e r - e r P n o i s u f r e p e r - t s o P NCM are visualized at sites of neutrophil recruitment and endothelial injury Human PGD LIPOSOMAL CLODRONATE DEPLETES Ly6Clow MONOCYTES IN PERFUSED LUNGS Control Clo-lip 87.1 73.2 12.9 26.5 Flushed Lung Ly6C MHC II Tissue monocytes Patrolling endothelial- bound monocytes Flushed Lung Ly6C MHC II Depletion of donor
    [Show full text]
  • HLA Overview
    4/12/2018 American Red Cross HLA Laboratories Playing with Matches Shonna Sims, MBA HLA Director American Red Cross [email protected] I have no real or I have no relevant apparent conflict of financial relationship to interest or other disclose. relationships related to the content of this presentation. American Red Cross 1 HLA Overview • HLA = Human Leukocyte Antigen • HPA = Human Platelet Antigen American Red Cross 2 1 4/12/2018 Human Leukocyte Antigen System • HLA Antigens are found on the surface of both platelets and white cells as well as on other nucleated cells of the body. • Platelets carry Class I HLA antigens and lack Class II antigens. American Red Cross 3 Human Leukocyte Antigen System (Class I Antigens) HLA –A, B, C Found on most body tissue cells Interact with cytotoxic T cells American Red Cross 4 Human Leukocyte Antigen System (Class II Antigens) HLA –DR, DP, DQ Limited Cellular Expression Interact with T-helper cells American Red Cross 5 2 4/12/2018 HLA Antibodies HLA antibodies can cause the destruction of transfused platelets. Sensitization may develop due to: • Pregnancy • Multiple transfusions American Red Cross 6 What about HPA? • Refractoriness can be caused by HPA (platelet glycoprotein) antibodies alone (<6% of patients – although I have seen <1%) or in combination with HLA antibodies (<10%). – Some HPA antibodies do not cause recognizable refractoriness due to low pathogenicity and/or low population antigen frequency (OR low titer)…. American Red Cross 7 What about Class II or Cw – they are on the report… • HLA Class II DR/DQ/DP are mainly of interest for bone marrow or tissue transplants, or disease association (DR).
    [Show full text]
  • Blood Product Administration in Children and Young Adults Likely to Need a Solid Organ Transplant October 2020
    Evidence-Based Care Guideline 50 Blood Product Administration in Children and Young Adults Likely to Need a Solid Organ Transplant October 2020 TARGET POPULATION FOR THE RECOMMENDATION Inclusion Criteria Children and young adults who are likely to require solid organ transplantation: For heart transplant, patients with: • single ventricle physiology • cardiac dysfunction • hypertrophic cardiomyopathy • restrictive heart disease For kidney transplant, patients with: • Chronic Kidney Disease (CKD) stage 3 or higher (estimated GFR of < 60 ml/min/1.73 m2) • on dialysis • under evaluation or waitlisted for kidney transplantation • have received a kidney transplant For liver transplant, patients with: • listed for liver transplantation • having received a liver transplant For lung transplant, patients with: • listed for transplantation • having received a lung transplant For small bowel transplant, patients with: • listed for transplantation • having received a small bowel transplant Exclusion Criteria Bone marrow transplant or hematopoietic stem cell transplant recipients EVIDENCE-BASED CARE RECOMMENDATIONS Clinical Assessment Care Recommendation Statement 1 It is strongly recommended that the theoretical future risk of allosensitization should not Recommendation Strength prevent or delay administration of blood products in patients with life threatening conditions Strong that could be reversed by blood product administration (Local Consensus, 2020 [5]). Care Recommendation Statement 2 It is strongly recommended that the decision to administer blood products consider all Recommendation Strength perceived risks and benefits in each individual patient (Scornik, 2013 [1a]). Strong • Note 1: This includes the risk of allosensitization, which has been associated with longer wait times and increased risk of rejection and mortality in patients who are in need of kidney or heart transplantation (Scornik, 2013 [1a]; McKee, 2018 [3a]; Ibrahim, 2011 [4a]).
    [Show full text]
  • Proposal for Crossmatch Project 18.10.12.Docx
    Aus der Klinik für kleine Haustiere des Fachbereichs Veterinärmedizin der Freien Universität Berlin Studies in feline pre-transfusion testing: Evaluating a novel blood typing device and serial cross-matching in transfusion patients Inauguraldissertation zur Erlangung des Grades eines Doktors der Veterinärmedizin an der Freien Universität Berlin Vorgelegt von Layla Hourani Tierärztin aus Rostock Berlin 2017 Journal-Nr.: 3990 Gedruckt mit Genehmigung des Fachbereichs Veterinä rmedizin der Freien Universitä t Berlin Dekan: Univ.-Prof. Dr. Jürgen Zentek Erster Gutachter: Univ.-Prof. Dr. Barbara Kohn Zweiter Gutachter: Univ.-Prof. Dr. Heidrun Gehlen Dritter Gutachter: Univ.-Prof. Dr. Robert Klopfleisch Deskriptoren (nach CAB-Thesaurus): blood type, blood typing, cat, cross-matching, pre- transfusion testing, point-of-care, transfusion medicine, transfusion safety Tag der Promotion: 19.07.2017 2 To Friedolin, Krikri, Molly, Spotty and the old gibbon couple at Sababurg Zoo 3 Table of contents LIST OF ABBREVIATIONS.....................................................................................................................6 TABLES AND FIGURES .........................................................................................................................7 1 INTRODUCTION ...........................................................................................................................8 1.1 HISTORY OF TRANSFUSION MEDICINE AND TRANSFUSION SAFETY .......................................................9 1.2 PATIENT SAFETY IN
    [Show full text]
  • Blood Grouping
    WHO GMP ANTISERA CERTIFIED ANTISERA J. MITRA Ensure Your Blood Compatibility with our Product Range... & CO. PVT. LTD. The ABO blood group system is a classification system for the antigens of human blood discovered by Karl Landsteiner in 1900. There are four blood groups : A, B, AB and O. The Rh blood group system is the second most significant system for blood grouping. Rh factor refer to Rh D antigen only. Determination of Rh factor along with ABO is essential for defining the Rh +ve or Rh -ve status of the individual. Around 85% of the human population is Rh +ve while 15% is Rh -ve. The ABO & Rh systems are the most significant blood group systems from the clinical point of view. JML Range of Blood Grouping... Anti-A Monoclonal Anti-B Monoclonal Anti-AB Monoclonal Anti-D (IgM) Rh1 Monoclonal Anti-D (IgG+IgM) Rh1 Monoclonal Anti-H Lectin Anti-A1 Lectin Anti Human Serum Bovine Albumin AANNTTII--HH LLEECCTTIINN AABBOO BBLLOOOODD GGRROOUUPPIINNGG Ulex europaeus lectin for slide and Tube Tests (Anti-A, Anti-B, Anti-AB, Anti-D (IgM) & Anti-D (IgG + IgM) Monoclonal) Anti-H Lectin is used to show the presence of Salient Features: The routine practice of blood typing and cross-matching blood products prevent adverse 'H' antigen on human red blood cells. The 'H' Excellent Avidity antigen is a precursor of A & B antigen. transfusion reactions caused by ABO antibodies. ABO blood grouping is used to check Clearly visible agglutination the RBCs & plasma compatibility of donor and recipient before blood transfusion. Individuals that test as type 'O' by ABO blood Shelf Life : 24 months at 2-8ºC group system may have Bombay Phenotype (hh).
    [Show full text]
  • The Immune System and Kidney Disease: Basic Concepts and Clinical Implications
    REVIEWS The immune system and kidney disease: basic concepts and clinical implications Christian Kurts1, Ulf Panzer2, Hans-Joachim Anders3 and Andrew J. Rees4 Abstract | The kidneys are frequently targeted by pathogenic immune responses against renal autoantigens or by local manifestations of systemic autoimmunity. Recent studies in rodent models and humans have uncovered several underlying mechanisms that can be used to explain the previously enigmatic immunopathology of many kidney diseases. These mechanisms include kidney-specific damage-associated molecular patterns that cause sterile inflammation, the crosstalk between renal dendritic cells and T cells, the development of kidney-targeting autoantibodies and molecular mimicry with microbial pathogens. Conversely, kidney failure affects general immunity, causing intestinal barrier dysfunction, systemic inflammation and immunodeficiency that contribute to the morbidity and mortality of patients with kidney disease. In this Review, we summarize the recent findings regarding the interactions between the kidneys and the immune system. Considerable progress has been made both in under- role of the cellular immune responses that drive renal 1Institutes of Molecular standing the basic immune mechanisms of kidney disease. Moreover, we summarize recent discoveries Medicine and Experimental disease and in translating these findings to clinical about complement- and antibody-mediated nephritis, Immunology (IMMEI), therapies. Sophisticated animal studies combined and we discuss kidney pathologies that are mediated Rheinische Friedrich- with the analysis of clinical samples have led to a pre- by renal autoantigen-specific antibodies, especially those Wilhelms-Universität, cise knowledge of the autoimmune targets and of the that are induced by crossreactive microorganism-specific Sigmund-Freud-Str. 25, 53105 Bonn, Germany. mechanisms responsible for kidney injury.
    [Show full text]
  • Multiplex Gene Analysis Reveals T-Cell and Antibody-Mediated Rejection
    www.nature.com/scientificreports OPEN Multiplex gene analysis reveals T‑cell and antibody‑mediated rejection‑specifc upregulation of complement in renal transplants Eva Vonbrunn1, Tajana Ries1, Stefan Söllner1, Janina Müller‑Deile2, Maike Büttner‑Herold1, Kerstin Amann1,3 & Christoph Daniel1,3* In renal transplantation, complement is involved in ischemia reperfusion injury, graft rejection and dysfunction. However, it is still unclear how induction of complement and its activation are initiated. Using allograft biopsies of a well‑characterized cohort of 28 renal transplant patients with no rejection (Ctrl), delayed graft function (DGF), acute T‑cell‑mediated (TCMR) or antibody‑mediated rejection (ABMR) we analyzed diferences in complement reaction. For that mRNA was isolated from FFPE sections, quantifed with a multiplex gene expression panel and correlated with transplant conditions and follow‑up of patients. Additionally, infammatory cells were quantifed by multiplex immunohistochemistry. In allograft biopsies with TCMR and ABMR gene expression of C1QB was 2‑4 fold elevated compared to Ctrl. In TCMR biopsies, mRNA counts of several complement‑related genes including C1S, C3, CFB and complement regulators CFH, CR1 and SERPING1 were signifcantly increased compared to Ctrl. Interestingly, expression levels of about 75% of the analyzed complement related genes correlated with cold ischemia time (CIT) and markers of infammation. In conclusion, this study suggest an important role of complement in transplant pathology which seems to be at
    [Show full text]